References

  • CFOQUEST® Product Monograph, Elvium Life Sciences, September 28, 2022.
  • CADDRA - Canadian ADHD Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition, Toronto ON; CADDRA, 2020.
  • Weiss MD, et al. Efficacy and safety of a long-acting multilayer-release methylphenidate formulation (PRC-063) in the treatment of adolescent Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind clinical trial with a 6-Month open-label extension. J Child Adolesc Psychopharmacol 2021;31(9):610-622.
  • Weiss MD, et al. Efficacy and safety of PRC-063, extended-release multilayer methylphenidate in adults with ADHD including 6-month open-label extension. J Attent Disor 2021;25(10):1417-1428.
  • CBiphentin® Product Monograph, Elvium Life Sciences, September 2, 2021.
  • CConcerta® Product Monograph, Janssen Inc., May 13, 2022.
  • Wigal SB, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998;34(1):47-53.
  • Ontario Drug Benefit Formulary: Edition 43. Available at: https:// www.formulary.health.gov.on.ca/formulary. Accessed April 25, 2023.
  • RAMQ List of Medications. Available at: https://www.ramq.gouv.qc.ca/sites/ default/files/documents/non_indexes/liste-med-2023-04-13-en.pdf. Accessed April 13, 2023.
  • Saskatchewan Formulary Bulletin. Bulletin #211. March 1, 2022.
  • Manitoba Drug Benefits and Manitoba Drug Interchangeability Formulary Amendment. Bulletin #114. Available at: https://www.gov.mb.ca/health/ mdbif/docs/bulletins/bulletin114.pdf. Accessed February 1, 2023.
  • Express Scripts® Drug Benefit List. Available at: https://nihb.express- scripts.ca/NIHBProvider/benefits/pharmacy?grid&benefit=pharmacy page=drugbenefit- . Accessed February 1, 2023.
  • Reiz JL, et al. Comparative bioavailability of single-dose methylphenidate
    from a multilayer-release bead formulation and an osmotic system
    A two-way crossover study in healthy young adults. Clin Ther 2008;30(1):59-69.